Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CESM for the Evaluation of Pathologic Nipple Discharge
NCT05056844Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2021
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Sensitivity of contrast enhancement of contrast enhanced spectral mammography (CESM) at 1 year. Started Apr 2021; status: active, not recruiting.
Beyond the preview
Go deeper on NCT05056844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05056844.